Skip to main content
WeightCited

CLA para Obesity

B

Cochrane meta-analysis of 18 RCTs (n=807) found CLA at 3.2 g/day reduced body fat mass by 1.33 kg over 6-12 months without significant change in body weight, suggesting lean mass preservation. A 2-year RCT (n=134) found sustained fat reduction. Effects are modest and require long-term use.

<\/script>\n
`; }, get iframeSnippet() { const domain = 'weightcited.com'; const params = 'ingredient\u003Dcla\u0026condition\u003Dobesity'; return ``; }, get activeSnippet() { return this.method === 'script' ? this.scriptSnippet : this.iframeSnippet; }, copySnippet() { navigator.clipboard.writeText(this.activeSnippet).then(() => { this.copied = true; setTimeout(() => { this.copied = false; }, 2000); }); } }" @keydown.escape.window="open = false" @click.outside="open = false">

Embed This Widget

Style



      
      
    

Widget powered by . Free, no account required.

B

Conclusión

Cochrane meta-analysis of 18 RCTs (n=807) found CLA at 3.2 g/day reduced body fat mass by 1.33 kg over 6-12 months without significant change in body weight, suggesting lean mass preservation. A 2-year RCT (n=134) found sustained fat reduction. Effects are modest and require long-term use.

Key Statistics

18

Estudios

807

Participantes

Positive

B

Calificación

Dosage & Usage

mg = milligrams · mcg = micrograms (1,000× smaller) · IU = International Units

Dosificaciones de uso común

general:
3.2-6.4 g/day mixed isomers
bodycomposition:
3.4 g/day (50:50 c9,t11:t10,c12 blend)
minimumeffective:
3.2 g/day for ≥12 weeks

Límite superior: 6 g/day; higher doses may worsen insulin sensitivity

Mejor momento para tomar: With meals; divide dose across 2-3 meals

Safety & Side Effects

Efectos secundarios reportados

  • GI discomfort
  • May worsen insulin sensitivity at high doses
  • Possible HDL reduction
  • Fatty liver (in some rodent studies)

Interacciones conocidas

  • Diabetes medications (may affect insulin sensitivity)
  • Blood thinners (theoretical)

Ingesta máxima tolerable: 6 g/day; higher doses may worsen insulin sensitivity

Consulte siempre a su profesional de salud antes de comenzar cualquier suplemento.Siempre consulte a su profesional de salud antes de comenzar cualquier suplemento.

Frequently Asked Questions

Does CLA help with Obesity?
Based on 18 studies with 807 participants, there is moderate evidence from clinical studies that CLA may support Obesity management. Our evidence grade is B (Good Evidence).
How much CLA should I take for Obesity?
Studies have used various dosages. A commonly studied range is 3.2-6.4 g/day mixed isomers. Always consult your healthcare provider before starting any supplement regimen.
Are there side effects of CLA?
Reported side effects may include GI discomfort, May worsen insulin sensitivity at high doses, Possible HDL reduction, Fatty liver (in some rodent studies). Most side effects are mild and dose-dependent. Consult your doctor if you experience any adverse reactions.
How strong is the evidence for CLA and Obesity?
We rate the evidence as Grade B (Good Evidence). This rating is based on 18 peer-reviewed studies with 807 total participants. The overall direction of effect is positive.

Related Evidence

Aviso legal FDA: Estas declaraciones no han sido evaluadas por la Food and Drug Administration. Los productos y la información en este sitio web no están destinados a diagnosticar, tratar, curar ni prevenir ninguna enfermedad. Las calificaciones de evidencia presentadas se basan en nuestro análisis de investigación publicada revisada por pares y no constituyen consejo médico. Siempre consulte a su profesional de salud antes de comenzar cualquier régimen de suplementos.